ASKA Pharmaceutical Holdings Co.,Ltd. [4886.T]
TOKYO, May 11 (Pulse News Wire) – Aska Pharmaceutical Holdings Co., Ltd. (4886.T) reported consolidated results for fiscal year 2026 ending March.
Revenue was ¥71.1 billion (+10.9% YoY). operating profit was ¥5,834 million (+9.4%). net profit attributable to shareholders was ¥5,424 million (+6.3%).
Total assets stood at ¥110 billion with an equity ratio of 62.5%. The company declared an annual dividend of ¥33 per share. The full-year forecast for the current fiscal year is revenue of ¥73.0 billion (+2.6%).
🟢 Confidence: High AI-translated content.